{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:49:16Z","timestamp":1758970156588},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.clinthera.2005.02.016","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T22:48:52Z","timestamp":1115419732000},"page":"273-285","source":"Crossref","is-referenced-by-count":4,"title":["The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use"],"prefix":"10.1016","volume":"27","author":[{"given":"Pierre","family":"Teillac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo V.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred P.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.02.016_bib1","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2004.04.579","article-title":"American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitivity metastatic, recurrent, orprogressive prostate cancer","volume":"22","author":"Loblaw","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib2","unstructured":"American Cancer Society. Cancer facts & figures 2004. Available at: http:\/\/www.cancer.org. Accessed January 5, 2005."},{"key":"10.1016\/j.clinthera.2005.02.016_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/theoncologist.8-3-259","article-title":"Management of high-risk populations with locally advanced prostate cancer","volume":"8","author":"Khan","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2005.02.016_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eursup.2003.12.005","article-title":"The role of hormonal therapy in the treatment of locally advanced prostate cancer-regional perspectives: USA","volume":"3","author":"Crawford","year":"2004","journal-title":"Eur Ural Suppl."},{"key":"10.1016\/j.clinthera.2005.02.016_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMra021562","article-title":"Prostate cancer","volume":"349","author":"Nelson","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2005.02.016_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.02.016_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0360-3016(00)80021-8","article-title":"RTOG protocol 9202: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction andradiotherapy in locally advanced carcinoma of the prostate","volume":"48","author":"Hanks","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clinthera.2005.02.016_bib8","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2005.02.016_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-5347(01)63917-X","article-title":"Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation","volume":"159","author":"Seay","year":"1998","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib10","first-page":"504","article-title":"Disease free survival in patients with pathological \u201cC STAGE\u201d prostate cancer at radical retropubic prostatectomy submitted to adjuvanthormonal treatment","volume":"38","author":"Prayer-Galetti","year":"2000","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","article-title":"Phase III trial of androgen suppression using goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy:Report of Radiation Therapy Oncology Group Protocol 85-31","volume":"15","author":"Pilepich","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","article-title":"Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppressionfollowing standard radiation therapy for unfavorable prognosis carcinoma of the prostate","volume":"49","author":"Lawton","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.02.016_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.urology.2003.08.004","article-title":"Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostatecancer","volume":"62","author":"Pisansky","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2005.02.016_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002512-200320020-00003","article-title":"Value of endocrine therapy for early and locally advanced prostate cancer","volume":"20","author":"Wirth","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2005.02.016_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","article-title":"Risk of prostate carcinoma death in patients with lymph node metastasis","volume":"91","author":"Cheng","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.02.016_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advancedcarcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clinthera.2005.02.016_bib17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0022-5347(01)63230-0","article-title":"Hormonal treatment before radical prostatectomy: A 3-year followup","volume":"159","author":"Aus","year":"1998","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000020366","article-title":"4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer","volume":"38","author":"Schulman","year":"2000","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized com parative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation follow ing radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.02.016_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0360-3016(03)00538-8","article-title":"Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy","volume":"57","author":"Pollack","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clinthera.2005.02.016_bib22","first-page":"1035","article-title":"Consensus statement: Guide lines for PSA following radiation therapy","volume":"37","author":"American Society for Therapeutic Radiology and Oncology Consensus Panel","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clinthera.2005.02.016_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.02.016_bib24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(00)00637-4","article-title":"Postradiotherapy prostate biopsies: What do they really mean? Results from 498 patients","volume":"48","author":"Crook","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clinthera.2005.02.016_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2","article-title":"Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy","volume":"86","author":"Kestin","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.02.016_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0167-8140(96)01770-7","article-title":"Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate","volume":"40","author":"Zietman","year":"1996","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0022-5347(01)65876-2","article-title":"Prostate specific antigen nadir following external beam radiation ther apy for clinically localized prostate cancer: The relationship between nadirlevel and disease-free survival","volume":"156","author":"Lee","year":"1996","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa032975","article-title":"Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy 0","volume":"351","author":"D'Amico","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2005.02.016_bib29","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2002.01.150","article-title":"Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy","volume":"20","author":"Kupelian","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1078-1439(03)00103-0","article-title":"Variables in predicting survival based on treating \u201cPSA-only\u201d relapse","volume":"21","author":"Moul","year":"2003","journal-title":"Urol Oncol."},{"issue":"Suppl 6B","key":"10.1016\/j.clinthera.2005.02.016_bib31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urology.2003.09.009","article-title":"Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer","volume":"62","author":"Cannon","year":"2003","journal-title":"Urology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.02.016_bib32","first-page":"5172","article-title":"Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long-term results of phase III RTOG study 85-31","volume":"57","author":"Pilepich","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clinthera.2005.02.016_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial 0","volume":"79","year":"1997","journal-title":"Br J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib34","first-page":"392","article-title":"Comparison of early versus late hormonal therapy (HT) following early PSA-only recurrence (ePSAR) within the Department of Defense Center forProstate Disease Research Database","volume":"22","author":"Reynolds","year":"2003"},{"key":"10.1016\/j.clinthera.2005.02.016_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.ju.0000113794.34810.d0","article-title":"Early versus delayed hormonal therapy for prostate specific antigen only recur rence of prostate cancer after radical prostatectomy","volume":"171","author":"Moul","year":"2004","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib36","series-title":"Protocol 30943","article-title":"European Organisation for Research and Treatment of Cancer (EORTC)","author":"Verbaeys","year":"2004"},{"key":"10.1016\/j.clinthera.2005.02.016_bib37","series-title":"Protocol SWOG9346","article-title":"Phase III randomized study of intermittent versus continuous com bined androgen-deprivation therapy comprising bicalutamide and goserelin in patients with metastatic stage IV prostate cancer responsive to such therapy","author":"Hussain","year":"2004"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.02.016_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2005.02.016_bib39","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/01.ju.0000091640.59812.83","article-title":"The effects of combined androgen blockade on cognitive function dur ing the first cycle of intermittent androgen suppression in patients withprostate cancer","volume":"170","author":"Cherrier","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bjc.6601235","article-title":"Androgen deprivation and cognition in prostate cancer","volume":"89","author":"Salminen","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2005.02.016_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1532-5415.2004.52067.x","article-title":"The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer","volume":"52","author":"Taxel","year":"2004","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.clinthera.2005.02.016_bib42","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","article-title":"Fracture risk following bilateral orchiectomy","volume":"169","author":"Melton","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib43","series-title":"Abstract presented at: American Society of Clinical Oncology 35th Annual Meeting","article-title":"Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittentandrogen suppression (IAS)","author":"Higano","year":"1999"},{"key":"10.1016\/j.clinthera.2005.02.016_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0305-7372(03)00076-8","article-title":"Management of treatment-related osteoporosis in men with prostate cancer","volume":"29","author":"Smith","year":"2003","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.clinthera.2005.02.016_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jc.87.2.599","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2005.02.016_bib46","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.clinthera.2005.02.016_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3322\/canjclin.52.3.154","article-title":"The current state of hormonal therapy for prostate cancer","volume":"52","author":"Hellerstedt","year":"2002","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.clinthera.2005.02.016_bib48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0302-2838(03)00375-0","article-title":"Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study","volume":"44","author":"Albrecht","year":"2003","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2005.02.016_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1464-410X.2003.04015.x","article-title":"Intermittent androgen suppression in patients with prostate cancer","volume":"91","author":"De La Taille","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2005.02.016_bib50","first-page":"4096","article-title":"Metastatic prostate cancer in a transgenic mouse","volume":"56","author":"Gingrich","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.clinthera.2005.02.016_bib51","first-page":"191","article-title":"Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations","volume":"4","author":"Bruchovsky","year":"2000","journal-title":"Mol Urol."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T09:40:32Z","timestamp":1550482832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0149291805000354"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.02.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}